BACKGROUND: Antiretroviral therapy (ART) is typically begun weeks after HIV diagnosis. We assessed the acceptability, feasibility, safety, and efficacy of initiating ART on the same day as diagnosis. METHODS: We studied a clinic-based cohort consisting of consecutive patients who were referred with new HIV diagnosis between June 2013 and December 2014. A subset of patients with acute or recent infection (<6 months) or CD4 <200 were managed according to a "RAPID" care initiation protocol. An intensive, same-day appointment included social needs assessment; medical provider evaluation; and a first ART dose offered after laboratories were drawn. Patient acceptance of ART, drug toxicities, drug resistance, and time to viral suppression outcomes were compared between RAPID participants and contemporaneous patients (who were not offered the program), and with an historical cohort. RESULTS: Among 86 patients, 39 were eligible and managed on the RAPID protocol. Thirty-seven (94.9%) of 39 in RAPID began ART within 24 hours. Minor toxicity with the initial regimen occurred in 2 (5.1%) of intervention patients versus none in the nonintervention group. Loss to follow-up was similar in intervention (10.3%) and nonintervention patients (14.9%) during the study. Time to virologic suppression (<200 copies HIV RNA/mL) was significantly faster (median 1.8 months) among intervention-managed patients when compared with patients treated in the same clinic under prior recommendations for universal ART (4.3 months; P = 0.0001). CONCLUSIONS: Treatment for HIV infection can be started on the day of diagnosis without impacting the safety or acceptability of ART. Same-day ART may shorten the time to virologic suppression.
BACKGROUND: Antiretroviral therapy (ART) is typically begun weeks after HIV diagnosis. We assessed the acceptability, feasibility, safety, and efficacy of initiating ART on the same day as diagnosis. METHODS: We studied a clinic-based cohort consisting of consecutive patients who were referred with new HIV diagnosis between June 2013 and December 2014. A subset of patients with acute or recent infection (<6 months) or CD4 <200 were managed according to a "RAPID" care initiation protocol. An intensive, same-day appointment included social needs assessment; medical provider evaluation; and a first ART dose offered after laboratories were drawn. Patient acceptance of ART, drug toxicities, drug resistance, and time to viral suppression outcomes were compared between RAPID participants and contemporaneous patients (who were not offered the program), and with an historical cohort. RESULTS: Among 86 patients, 39 were eligible and managed on the RAPID protocol. Thirty-seven (94.9%) of 39 in RAPID began ART within 24 hours. Minor toxicity with the initial regimen occurred in 2 (5.1%) of intervention patients versus none in the nonintervention group. Loss to follow-up was similar in intervention (10.3%) and nonintervention patients (14.9%) during the study. Time to virologic suppression (<200 copies HIV RNA/mL) was significantly faster (median 1.8 months) among intervention-managed patients when compared with patients treated in the same clinic under prior recommendations for universal ART (4.3 months; P = 0.0001). CONCLUSIONS: Treatment for HIV infection can be started on the day of diagnosis without impacting the safety or acceptability of ART. Same-day ART may shorten the time to virologic suppression.
Authors: Bluma G Brenner; Michel Roger; David Stephens; Daniela Moisi; Isabelle Hardy; Jonathan Weinberg; Reuven Turgel; Hugues Charest; James Koopman; Mark A Wainberg Journal: J Infect Dis Date: 2011-10-01 Impact factor: 5.226
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Christopher D Pilcher; George Joaki; Irving F Hoffman; Francis E A Martinson; Clement Mapanje; Paul W Stewart; Kimberly A Powers; Shannon Galvin; David Chilongozi; Syze Gama; Matthew A Price; Susan A Fiscus; Myron S Cohen Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Katerina A Christopoulos; Nicola M Zetola; Jeffrey D Klausner; Barbara Haller; Brian Louie; C Bradley Hare; Mark Pandori; Patricia Nassos; Marguerite Roemer; Christopher D Pilcher Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: T Déirdre Hollingsworth; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks; Christophe Fraser Journal: J Infect Dis Date: 2014-12-26 Impact factor: 5.226
Authors: Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow Journal: PLoS One Date: 2009-05-18 Impact factor: 3.240
Authors: Brettania L W Lopes; Joseph J Eron; Michael J Mugavero; William C Miller; Sonia Napravnik Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: Constance A Benson; Judith S Currier; Carlos Del Rio; Joel E Gallant; Roy M Gulick; Jeanne M Marrazzo; Douglas D Richman; Michael S Saag; Robert T Schooley; Paul A Volberding Journal: Top Antivir Med Date: 2017 Dec/Jan
Authors: S Perez-Patrigeon; A Camiro-Zúñiga; M R Jaramillo-Jante; P F Belaunzarán-Zamudio; B Crabtree-Ramírez; L E Soto-Ramírez; J J Calva; C Hernández-León; J L Mosqueda-Gómez; S Navarro-Alvarez; J G Sierra-Madero Journal: HIV Med Date: 2019-03-29 Impact factor: 3.180
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2018-06-13 Impact factor: 2.205
Authors: Kara G Marson; Robert Marlin; Phong Pham; Stephanie E Cohen; Diane Jones; Marguerite Roemer; Philip J Peters; Barbara Haller; Christopher D Pilcher Journal: J Clin Virol Date: 2017-04-07 Impact factor: 3.168